KR900004722A - 푸마길롤 유도체 - Google Patents

푸마길롤 유도체 Download PDF

Info

Publication number
KR900004722A
KR900004722A KR1019890012548A KR890012548A KR900004722A KR 900004722 A KR900004722 A KR 900004722A KR 1019890012548 A KR1019890012548 A KR 1019890012548A KR 890012548 A KR890012548 A KR 890012548A KR 900004722 A KR900004722 A KR 900004722A
Authority
KR
South Korea
Prior art keywords
substituted
compound
group
alkyl
carbamoyl
Prior art date
Application number
KR1019890012548A
Other languages
English (en)
Other versions
KR0138530B1 (ko
Inventor
또쇼지 기시모
다께시 후지따
Original Assignee
우메모또 요시마사
다께다야꾸힝고오교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우메모또 요시마사, 다께다야꾸힝고오교 가부시끼가이샤 filed Critical 우메모또 요시마사
Publication of KR900004722A publication Critical patent/KR900004722A/ko
Application granted granted Critical
Publication of KR0138530B1 publication Critical patent/KR0138530B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/28—Ethers with hydroxy compounds containing oxirane rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

내용 없음

Description

푸마길롤 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (20)

  1. 하기 일반식(I)의 화합물 또는 그의 염.
    (식중, R1은 치환될 수 있는 2-메틸-1-프로페닐 또는 이소부틸기이고, R2는 (1) 치환알카노일기, (2) C2-6알킬, 아미노, 할로겐, 히드록실, 저급알콕시, 시아노, 카르바모일 및 카르복실로 이루어진 군에서 선택된 적어도 하나의 치환체를 갖는 치환아로일기, (3) 임의로 치환될 수 있는 방향족 헤테로사이클-카르보닐, (4) 임의로 치환될 수 있는 카르바모일기, (5) 임의로 치환될 수 있는 알킬기, (6) 임의로 치환될 수 있는 벤젠술포닐기, (7) 임의로 치환될 수 있는 알킬술포닐기, (8) 임의로 치환될 수 있는 술파모일기, (9) 임의로 치환될 수 있는 알콕시카르보닐기, 또는 (10) 임의로 치환될 수 있는 페녹시카르보닐기이다.)
  2. 제1항에서 있어서, R1이 히드록시 또는 디알킬아미노에 의해 치환될 수있는 2-메틸-1-프로페닐기인 화합물.
  3. 제1항에 있어서, R2가 아미노, C1-6알킬아미노, 이-C1-6알킬아미노, 니트로, 할로겐, C1-6알콕시, 시아노, 카르바모일, 카르복실, C1-6알킬카르복시, 카르복시-C1-6알콕시, 치환될 수 있는 페닐 또는 치환 될 수 있는 방향족 헤테로사이클 고리에 의해 치환된 C2-6알카노일기인 화합물.
  4. 제1항에 있어서, R2가 C2-6알킬, 아미노, 할로겐, 히드록시, C1-6알콕시, 시아노 카르바모일 또는 카르복실에 의해 치환된 벤조일 또는 나프토일기인 화합물.
  5. 제1항에 있어서, R2가 푸로일, 테노일, 니코티노일, 이소니코티노일 및 이미다졸-1-카르보닐에서 선택된 방향족 헤테로 사이클-카르보닐인 화합물.
  6. 제1항에 있어서, R2가 1∼3치환체를 갖거나 카르바모일 질소원자와 함께 치환체를 가질 수 있는 5- 또는 6-원 헤테로사이클 고리를 형성할 수 있는 C1-6알킬, 불포화될 수 있는 C1-6알카노일, 페닐, 나프틸, 벤조일, 방향족 헤테로사이클 고리를 형성할 수 있는 C1-6알킬, 불포화될 수 있는 C1-6알카노일, 페닐, 나프틸, 벤조일, 방향족 헤테로사이클-카르보닐, 아미노, 카르바모일, C1-6알킬알킬옥시카르보닐 또는 페녹시카르보닐에 의해 치환될 수 있는 카르바모일인 화합물.
  7. 제6항에 있어서, 치환체가 할로겐, 트리플루오로메틸, C1-6알킬, 이-C1-3알킬아미노, 니트로 C1-6알카노일옥시, C1-6알카노일옥시티오, 페닐티오 또는 방향족 헤테로 사이클티오일 화합물.
  8. 제1항에 있어서, R2가 에폭시화될 수 있고, 카르복실, 피리딜, 나프틸 또는 치환될 수 있는 페닐에 의해 치환될 수 있는 C1-6알킬인 화합물.
  9. 제1항에 있어서, R2가 C1-6알킬 또는 할로겐에 의해 치환될수 있는 벤젠술포닐인 화합물.
  10. 제1항에 있어서, R2가 C1-6알킬술포닐인 화합물.
  11. 제1항에 있어서, R2가 C1-6알킬 또는 페닐에 의해 치환될 수 있는 술파모일인 화합물.
  12. 제1항에 있어서, R2가 할로겐에 의해 치환될 수 있는 C1-6알콕시카르보닐인 화합물.
  13. 제1항에 있어서, R2가 C1-6알킬 또는 할로겐에 의해 치환될 수 있는 페놀시카르보닐인 화합물.
  14. 제1항에 있어서, R1이 히드록실에 의해 치환될 수 있는 2-메틸-1-프로페닐이고 R2가 할로게노아세틸에 의해 치환될 수 있는 카르바모일인 화합물.
  15. 제1항에 있어서, R2이 이소부틸이고 R2가 하로게노아세틸에 의해 치환될 수 있는 카르바모일인 화합물.
  16. 제1항에 있어서, 0-클로로아세틸카르바모일푸마길롤인 화합물.
  17. 제1항에 있어서, 0-카르바모일푸마길롤인 화합물.
  18. 제1항에 있어서, 0-클로로아세틸카르바모일디히드로푸마길롤인 화합물.
  19. 제1항에 있어서, 0-클로로아세틸카르바모일-6'b-히드록시푸마길롤인 화합물.
  20. 하기일반식의 화합물을 아실화, 카르바모일화, 알킬화 또는 술포닐화시킴을 특징으로 하는 청구범위 제1항에 따른 화합물의 제조방법.
    (식중, R1은 치환될 수 있는 2-메틸-1-프로페닐 또는 이소부틸기이다.)
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890012548A 1988-09-01 1989-08-31 푸마길롤 유도체 KR0138530B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP21928788 1988-09-01
JP63-219287 1988-09-01
JP88-219287 1988-09-01
JP89-053537 1989-03-06
JP5353789 1989-03-06
JP???? 1991-03-27

Publications (2)

Publication Number Publication Date
KR900004722A true KR900004722A (ko) 1990-04-12
KR0138530B1 KR0138530B1 (ko) 1998-05-15

Family

ID=26394244

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890012548A KR0138530B1 (ko) 1988-09-01 1989-08-31 푸마길롤 유도체

Country Status (7)

Country Link
US (1) US5698586A (ko)
EP (2) EP0359036B1 (ko)
KR (1) KR0138530B1 (ko)
AT (1) ATE150750T1 (ko)
DE (1) DE68927904T2 (ko)
ES (1) ES2099064T3 (ko)
GR (1) GR3023745T3 (ko)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
US6017954A (en) * 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
TW282399B (ko) * 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
EP0470569B1 (en) * 1990-08-08 1995-11-22 Takeda Chemical Industries, Ltd. Intravascular embolizing agent containing angiogenesis inhibiting substance
NZ240214A (en) 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
EP1004318A3 (en) * 1991-06-21 2002-08-07 Takeda Chemical Industries, Ltd. Cyclodextrin composition
US6476011B1 (en) 1991-08-28 2002-11-05 Sterix Limited Methods for introducing an estrogenic compound
US6011024A (en) 1991-08-28 2000-01-04 Imperial College Of Science Technology & Medicine Steroid sulphatase inhibitors
US6903084B2 (en) 1991-08-29 2005-06-07 Sterix Limited Steroid sulphatase inhibitors
EP0582459B1 (en) 1992-08-07 1998-01-07 Takeda Chemical Industries, Ltd. Production of microcapsules of water-soluble drugs
DE69311278T2 (de) * 1992-12-16 1997-10-30 Takeda Chemical Industries Ltd Stabile pharmazeutische Zubereitung mit Fumagillolderivaten
US5290887A (en) * 1993-04-30 1994-03-01 The Dow Chemical Company Epoxy resins containing thiadiazole and/or oxadiazole moieties
US5387657A (en) * 1993-09-10 1995-02-07 The Dow Chemical Company Epoxy resins containing thiadiazole and/or oxadiazole moieties
AU3533395A (en) * 1994-09-30 1996-04-26 Takeda Chemical Industries Ltd. Oral sustained-release preparation
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
US5710148A (en) * 1995-03-06 1998-01-20 Senju Pharmaceuticals Co., Ltd. Corneal opacification inhibitory composition
US5837281A (en) 1995-03-17 1998-11-17 Takeda Chemical Industries, Ltd. Stabilized interface for iontophoresis
US5908400A (en) * 1996-06-20 1999-06-01 Hisamitsu Pharmaceutical Co., Inc. Device structure for iontophoresis
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
US5801012A (en) 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin
US6265388B1 (en) 1997-03-21 2001-07-24 President And Fellows Of Harvard College Antisense inhibition of angiogenin expression
US6207704B1 (en) 1997-06-09 2001-03-27 Massachusetts Institute Of Technology Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
WO1999058126A1 (en) 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
WO1999061432A1 (en) * 1998-05-12 1999-12-02 Biochem Pharma Inc. Fumagillin analogs and their use as angiogenesis inhibitors
US8197430B1 (en) 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US6537554B1 (en) 1998-09-10 2003-03-25 Curagen Corporation Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
AU6409499A (en) 1998-10-01 2000-04-17 Children's Medical Center Corporation Method of treatment of cardiovascular injuries
JP4414517B2 (ja) 1999-09-01 2010-02-10 久光製薬株式会社 イオントフォレーシス用デバイス構造体
WO2001037873A2 (en) 1999-11-10 2001-05-31 Lentz M Rigdon Method and system to remove cytokine inhibitor in patients
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
US7335650B2 (en) 2000-01-14 2008-02-26 Sterix Limited Composition
US20030104573A1 (en) * 2000-09-11 2003-06-05 Shimkets Richard A. Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
PL366216A1 (en) 2000-11-01 2005-01-24 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US6919307B2 (en) 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US7105482B2 (en) 2000-11-01 2006-09-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
EP1436286B1 (en) * 2001-09-27 2009-08-19 Equispharm Co., Ltd. Fumagillol derivatives and preparing method thereof
FR2832149B1 (fr) * 2001-11-09 2006-01-06 Galderma Res & Dev Nouveaux inhibiteurs de l'angiogenese et leur utilisation pharmaceutique et cosmetique
US6803382B2 (en) 2001-11-09 2004-10-12 Galderma Research & Development, S.N.C. Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
CA2480666C (en) * 2002-04-11 2012-03-06 Children's Medical Center Corporation Tnp-470 polymer conjugates and use thereof
AU2003226349B2 (en) * 2002-04-11 2008-01-31 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
US20050176620A1 (en) * 2002-06-21 2005-08-11 Prestwich Glenn D. Crosslinked compounds and methods of making and using thereof
US8324184B2 (en) 2003-05-15 2012-12-04 University Of Utah Research Foundation Anti-adhesion composites and methods of use thereof
US20100330143A1 (en) 2003-12-04 2010-12-30 University Of Utah Research Foundation Modified macromolecules and methods of making and using thereof
US7981871B2 (en) * 2003-12-04 2011-07-19 University Of Utah Research Foundation Modified macromolescules and associated methods of synthesis and use
EP1699812A2 (en) * 2003-12-29 2006-09-13 Praecis Pharmaceuticals Inc. Inhibitors of methionine aminopeptidase-2 and uses thereof
KR100552043B1 (ko) * 2004-02-28 2006-02-20 주식회사종근당 푸마질롤 유도체를 포함하는 비만치료용 조성물
CA2570884C (en) 2004-06-16 2016-04-19 Jack Arbiser Carbazole formulations for the treatment of psoriasis and angiogenesis
US20080248030A1 (en) * 2005-02-02 2008-10-09 Children's Medical Center Corporation Method of Treating Angiogenic Diseases
US20070065514A1 (en) 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
US8747870B2 (en) 2006-04-20 2014-06-10 University Of Utah Research Foundation Polymeric compositions and methods of making and using thereof
US20100285094A1 (en) * 2006-04-20 2010-11-11 University Of Utah Research Foundation Polymeric compositions and methods of making and using thereof
EP2038309A2 (en) * 2006-07-11 2009-03-25 University of Utah Research Foundation Macromolecules modified with electrophilic groups and methods of making and using thereof
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
US8399512B2 (en) * 2007-11-28 2013-03-19 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
WO2010009374A1 (en) 2008-07-18 2010-01-21 Zafgen, Inc. Methods of treating an overweight or obese subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
CA2777108A1 (en) 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
KR20110039842A (ko) * 2009-10-12 2011-04-20 주식회사 바이오씨에스 이미다졸 화합물을 유효성분으로 포함하는 안구의 혈관 신생 관련 질환의 예방 및 치료용 조성물
AU2011204267B2 (en) 2010-01-08 2015-12-03 Zafgen Corporation Fumagillol type compounds and methods of making and using same
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
WO2011088055A2 (en) 2010-01-12 2011-07-21 Zafgen Corporation Methods and compositions for treating cardiovascular disorders
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
EP2595988B1 (en) 2010-07-22 2014-12-17 Zafgen, Inc. Tricyclic compounds and methds of making and using same
NZ610569A (en) 2010-11-09 2015-06-26 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
WO2012064928A1 (en) 2010-11-10 2012-05-18 Zafgen Corporation Methods and compositions for treating thyroid hormone related disorders
CA2819251A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol
US20130316994A1 (en) 2010-11-29 2013-11-28 Zafgen, Inc. Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors
US9189078B2 (en) 2010-12-20 2015-11-17 Apple Inc. Enhancing keycap legend visibility with optical components
CA2825408A1 (en) 2011-01-26 2012-08-02 Zafgen, Inc. Tetrazole compounds and methods of making and using same
WO2012122264A1 (en) 2011-03-08 2012-09-13 Zafgen Corporation Oxaspiro [2.5] octane derivatives and analogs
WO2012154676A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Partially saturated tricyclic compounds and methods of making and using same
JP5941981B2 (ja) 2011-05-06 2016-06-29 ザフゲン，インコーポレイテッド 三環式スルホンアミド化合物ならびにその製造および使用方法
EP2705035B1 (en) 2011-05-06 2016-12-14 Zafgen, Inc. Tricyclic pyrazole sulfonamide compounds and methods of making and using same
WO2013010045A1 (en) 2011-07-12 2013-01-17 Biotime Inc. Novel methods and formulations for orthopedic cell therapy
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
US9440943B2 (en) 2012-01-18 2016-09-13 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
WO2013109739A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
US9260419B2 (en) 2012-05-07 2016-02-16 Zafgen, Inc. Polymorphic salt of a metap-2 inhibitor and methods of making and using same
MX2014013599A (es) 2012-05-08 2015-05-11 Zafgen Inc Tratamiento de la obesidad hipotalamica con inhibidores de metap2.
MX356755B (es) 2012-05-09 2018-06-11 Zafgen Inc Compuestos de tipo fumagilol y metodos para su elaboración y uso.
EP2917197B1 (en) 2012-11-05 2019-06-05 Zafgen, Inc. Tricyclic compounds and methods of making and using same
WO2014071369A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
CA2904353A1 (en) 2013-03-14 2014-09-25 Zafgen, Inc. Methods of treating renal disease and other disorders
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL67646A0 (en) 1982-01-15 1983-05-15 Lilly Co Eli Ascorbic acid ethers and related compounds
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
JP2544136B2 (ja) 1986-05-23 1996-10-16 第一製薬株式会社 硫酸化多糖体ｄｓ４１５２を含有する血管新生抑制剤及び抗腫瘍剤
CA1333363C (en) * 1988-01-19 1994-12-06 Judah Folkman Angiogenesis inhibitor comprising fumagillin
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US4954496A (en) * 1988-08-12 1990-09-04 Fujisawa Pharmaceutical Company, Ltd. Cyclohexane derivatives and pharmaceutical compositions
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
ES2053890T3 (es) * 1988-09-01 1994-08-01 Takeda Chemical Industries Ltd Agente inhibidor de la angiogenesis.

Also Published As

Publication number Publication date
EP0682020A1 (en) 1995-11-15
DE68927904D1 (de) 1997-04-30
ATE150750T1 (de) 1997-04-15
ES2099064T3 (es) 1997-05-16
GR3023745T3 (en) 1997-09-30
EP0359036A1 (en) 1990-03-21
DE68927904T2 (de) 1997-09-04
US5698586A (en) 1997-12-16
EP0359036B1 (en) 1997-03-26
KR0138530B1 (ko) 1998-05-15

Similar Documents

Publication Publication Date Title
KR900004722A (ko) 푸마길롤 유도체
KR900004333A (ko) 맥관 형성 억제제
PT96897A (pt) Processo para a preparacao de novos compostos aril-e heteroariletilenicos e de composicoes farmaceuticas que os contem
PT95389A (pt) Processo para a preparacao de novos derivados pirazolicos com accao anti-inflamatoria
NO900306L (no) Fremgangsmaate for fremstilling av nye pyrazolopyridin-forbindelser.
NO950009L (no) Heterocykliske forbindelser som farmasöytika
KR960007610A (ko) N-아실-5-플루오로시티딘 유도체의 제조 방법
MX9200817A (es) Derivados de piranil cianoguanidina y proceso para su preparacion.
PT88410A (pt) Process for preparing thiazolidinedione derivatives
DE69016899D1 (de) Thiazolidinedionederivate.
KR920701162A (ko) 퀴놀린 유도체, 당해 유도체를 함유하는 항궤양제 및 당해 유도체의 제조방법
ES2031865T3 (es) Un procedimiento para preparar derivados de imidas.
KR850002970A (ko) 시클로헥세놀 유도체의 제조방법
US4107317A (en) Chroman derivatives
ATE177096T1 (de) 4-substituierte 1,2,4-triazolderivate
KR920701120A (ko) 치환된 비시클로헵탄디온 유도체
KR860008111A (ko) 인딘과 나프탈렌 유도체의 제조방법
KR880012553A (ko) 디히드로피리딘아미드, 그의 제조방법 및 의약품으로서의 용도
KR840006482A (ko) 디히드로피라졸로 [3,4-b]피리딘 유도체의 제조방법
KR900003177A (ko) 테트라시클릭계 우울증 치료제
KR900003179A (ko) 벤조디아제핀 화합물 및 약제로서의 이의 용도
KR970061891A (ko) 신규한 헤테로아릴-옥사졸리디논
KR860006450A (ko) 5-클로로-1,3,4-티아디아졸-2-일옥시-아세트-아미드의 제조방법
KR880005138A (ko) 신규 화합물들
KR930021629A (ko) 피페라진 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090209

Year of fee payment: 12

LAPS Lapse due to unpaid annual fee